Advanced search
Publication Cover
International Reviews of Immunology Volume 21, 2002 - Issue 2-3
Submit an article Journal homepage
92
Views
89
CrossRef citations to date
0
Altmetric
Research Article

TH1 AND TH2 RESPONSES IN PATHOGENESIS AND REGULATION OF EXPERIMENTAL AUTOIMMUNE UVEORETINITIS

RACHEL R. CASPI National Eye Institute, National Institute of Health, Bethesda, Maryland, USA
Pages 197-208 | Published online: 03 Aug 2009

  • R.R. Caspi, Experimental autoimmune uveoretinitis-Rat and mouse. In I.R. Cohenand A. Miller, eds., Animal Models for Autoimmune Diseases: A Guidebook, pp. 57-81, Academic Press, San Diego, CA, 1994.
  • I. Gery, M. Mochizuki, and R.B. Nussenblatt, Retinal specific antigens and immunopathogenic processes they provoke. Prog. Retinal Res., 5: 75-109, 1986.
  • G. Adamus and C.-C. Chan, Experimental autoimmune uveitides: Multiple antigens, diverse diseases. International Reviews of Immunology, 21(2-3): 209-229, 2002.
  • I. Gery and J.W. Streilein, Autoimmunity in the eye and its regulation. Curr. Opin. Immunol., 6: 938-945, 1994.
  • R.B. Nussenblatt, S.M. Whitcup, and A.G. Palestine, Uveitis: Fundamentals and Clinical Practice, 2nd ed. St. Louis, MO: Mosby, 1996.
  • G. Pennesi and R.R. Caspi, Genetic control of susceptibility in clinical and experimental uveitis. International Reviews of Immunology, 21(2-3): xx-xx, 2002.
  • R.R. Caspi, IL-12 in autoimmunity. Clin. Immunol. Immunopathol., 88: 4-13, 1998.
  • B. Charlton and K.J. Lafferty, The Thl/Th2 balance in autoimmunity. Curr. Opin. Immunol., 7: 793-798, 1995.
  • A. Saoudi, J. Kuhn, K. Huygen, Y. de Kozak, T. Velu, M. Goldman, P. Druet, and B. Bellon, TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease. Eur. J. Immunol., 23: 3096-3103, 1993.
  • L.V. Rizzo, H. Xu, C.-C. Chan, B. Wiggert, and R.R. Caspi, IL-10 has a protective role in experimental autoimmune uveoretinitis. Int. Immunol., 10: 807-814, 1998.
  • M. Rocken, M. Racke, and E.M. Shevach, IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol. Today, 17: 225-231, 1996.
  • L. Adorini, J.C. Guery, and S. Trembleau, Manipulation of the Th1/Th2 cell balance: An approach to treat human autoimmune diseases? Autoimmunity, 23: 53-68, 1996.
  • H. Xu, L.V. Rizzo, R.B. Silver, and R.R. Caspi, Uveitogenicity is associated with a Thl-like lymphokine profile: Cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis. Cell. Immunol., 178: 69-78, 1997.
  • R.R. Caspi, R.B. Silver, C.-C. Chan, B. Sun, R.K. Agarwal, J. Wells, S. Oddo, Y. Fujino, F. Najafian, and R.L. Wilder, Genetic susceptibility to experimental autoimmune uveoretinitis in the rat is associated with an elevated Th1 response. J. Immunol., 157: 2668-2675, 1996.
  • T.K. Tarrant, R.B. Silver, C.-C. Chan, B. Wiggert, and R.R. Caspi, Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis. J. Immunol., 161: 122-127, 1998.
  • R.R. Caspi, B. Sun, R.K. Agarwal, R.B. Silver, L.V. Rizzo, C.-C. Chan, B. Wiggert, and R.L. Wilder, T cell mechanisms in experimental autoimmune uveoretinitis: Susceptibility is a function of the cytokine response profile. Eye, 11: 209-212, 1997.
  • B. Sun, L.V. Rizzo, S.H. Sun, C.-C. Chan, B. Wiggert, R.L. Wilder, and R.R. Caspi, Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper-2-like response. J. Immunol., 159: 1004-1011, 1997.
  • R.B. Silver, C.-C. Chan, B. Wiggert, and R.R. Caspi, The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment. Invest. Ophthalmol. Vis. Sci., 40: 2898-2905, 1999.
  • G. Yap, M. Pesin, and A. Sher, Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii. J. Immunol., 165: 628-631, 2000.
  • L. Stobie, S. Gurunathan, C. Prussin, D.L. Sacks, N. Glaichenhaus, C.Y. Wu, and R.A. Seder, The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc. Natl. Acad. Sci. USA, 97: 8427-8432, 2000.
  • I.J. Fuss, T. Marth, M.F. Neurath, G.R. Pearlstein, A. Jain, and W. Strober, Antiinterleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology, 117: 1078-1088, 1999.
  • P.A. Moreland T.B. Oriss, Crossregulation between Th1 and Th2 cells. Crit. Rev. Immunol., 18: 275-303, 1998.
  • A. Saoudi, B. Bellon, Y. de Kozak, J. Kuhn, M.C. Vial, B. Thillaye, and P. Druet, Prevention of experimental autoimmune uveoretinitis and experimental autoimmune pinealitis in (Lewis x Brown-Norway) F1 rats by HgC12 injections. Immunology, 74: 348-354, 1991.
  • R.R. Caspi, C.-C. Chan, B.C. Grubbs, R.B. Silver, B. Wiggert, C.F. Parsa, S. Bahmanyar, A. Billiau, and H. Heremans, Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice. J. Immunol., 152: 890-899, 1994.
  • K. Vermeire, H. Heremans, M. Vandeputte, S. Huang, A. Billiau, and P. Matthys, Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J. Immunol., 158: 5507-5513, 1997.
  • H. Heremans, C. Dillen, M. Groenen, E. Martens, and A. Billiau, Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: Enhancement by monoclonal antibodies against interferon-gamma. Eur. J. Immunol., 26: 2393-2398, 1996.
  • L.S. Jones, L.V. Rizzo, R.K. Agarwal, T.K. Tarrant, C.C. Chan, B. Wiggert, and R.R. Caspi, IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J. Immunol., 158: 5997-6005, 1997.
  • R.B. Silver, T.K. Tarrant, C.-C. Chan, B. Wiggert, and R.R. Caspi, Mice deficient in inducible nitric oxide synthase are susceptible to experimental autoimmune uveoretinitis. Invest. Ophthalmol. Vis. Sci., 40: 1280-1284, 1999.
  • S. Hoey, R.S. Grabowski, S.H. Ralston, J.V. Forrester, and J. Liversidge, Nitric oxide accelerates the onset and increases the severity of experimental autoimmune uveoretinitis through an IFN-gamma-dependent mechanism. J. Immunol., 159: 5132-5142, 1997.
  • J.J. Lafaille, F.V. Keere, A.L. Hsu, J.L. Baron, W Haas, C.S. Raine, and S. Tonegawa, Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med., 186: 307-312, 1997.
  • I. Gery and C. Egwuagu, Central tolerance mechanisms in control of susceptibility to autoimmune uveitic disease. International Rev. Immunol., 21(2-3): 89-100, 2002.
  • B. Bielekova, B. Goodwin, N. Richert, I. Cortese, T Kondo, G., Afshar, B. Gran, J. Eaton, J. Antel, J.A. Frank, H.F. McFarland, and R. Martin, Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat. Med., 6: 1167-1175, 2000.
  • L. Kappos, G. Comi, H. Panitch, J. Oger, J. Antel, P. Conlon, and L. Steinman, Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The altered peptide ligand in relapsing MS study group. Nat. Med., 6: 1176-1182, 2000.
  • J.F. Bach, Non-Th2 regulatory T-cell control of Th1 autoimmunity. Scand. J. Immunol., 54: 21-29, 2001.
  • G.J. Prud'hommeand C.A. Piccirillo, The inhibitory effects of transforming growth factor-beta-1 (TGF-betal) in autoimmune diseases. J. Autoimmun., 14: 23-42, 2000.
  • G.J. Thorbecke, D.T. Umetsu, R.H. deKruyff, G. Hansen, L.Z. Chen, and G.M. Hochwald, When engineered to produce latent TGF-betal, antigen specific T cells down regulate Th1 cell-mediated autoimmune and Th2 cell-mediated allergic inflammatory processes. Cytokine Growth Factor Rev., 11: 89-96, 2000.
  • H. Groux, A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J.E. deVries, and M.G. Roncarolo, A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature, 389: 737-742, 1997.
  • T.B. Connor, Jr., A.B. Roberts, M.B. Sporn, D. Danielpour, L.L. Dart, R.G. Michels, S. de Bustros, C. Enger, H. Kato, M. Lansing, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J. Clin. Invest., 83: 1661-1666, 1989.
  • A. Billiau, H. Heremans, F. Vandekerckhove, R. Dijkmans, H. Sobis, E. Meulepas, and H. Carton, Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J. Immunol., 140: 1506-1510, 1988.
  • T.K. Tarrant, P.B. Silver, J.L. Wahlsten, L.V. Rizzo, C.-C. Chan, B. Wiggert, and R.R. Caspi, Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis. J. Exp. Med., 189: 219-230, 1999.
  • H. KoIb and V. Kolb-Bachofen, Nitric oxide in autoimmune disease: Cytotoxic or regulatory mediator? Immunol. Today, 19: 556-561, 1998.
  • C.Q. Chu, S. Wittmer, and D.K. Dalton, Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J. Exp. Med., 192: 123-128, 2000.
  • G. Kassiotis and G. Kollias, Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: Implications for pathogenesis and therapy of autoimmune demyelination. J. Exp. Med., 193: 427-434, 2001.
  • L.V. Rizzo, A.L. Vallochi, D. Schlesinger, M.C. Martins, and R. Belfort Jr., The role of inflammatory and anti-inflammatory cytokines in the progression of experimental autoimmune uveitis. J. Immunol. AAI/CIS Annual meeting, Seattle, WA: (Abstract # 52.24), 2000.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.